The therapeutic potential of this approach was demonstrated as early as 1988 when a single-arm study found an objective response rate of 60% in chemotherapy-refractory metastatic melanoma patients treated with autologous tumour-infiltrating lymphocytes (TILs) without prior exposure to high-dose IL2 and 40% in patients who had previously received IL-2 [4]. This evidence concerns the gene IL2 and neoplasm.